|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:benefits
|
pain relief
cognitive enhancement
improved mood
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
Phase 1
Phase 2
|
|
gptkbp:collaborator
|
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:National_Institutes_of_Health
|
|
gptkbp:developed_by
|
gptkb:Vista_Gen_Therapeutics
|
|
gptkbp:discovery_year
|
gptkb:2010
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AV-101
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investigates
|
gptkb:neurodegenerative_diseases
gptkb:post-traumatic_stress_disorder
schizophrenia
anxiety disorders
bipolar disorder
cognitive impairment
|
|
gptkbp:market_position
|
not yet approved
|
|
gptkbp:mechanism_of_action
|
NMDA receptor antagonist
|
|
gptkbp:project
|
clinical trials
late stage
early stage
mid stage
|
|
gptkbp:regulatory_compliance
|
under review
investigational new drug
|
|
gptkbp:research
|
clinical
preclinical
|
|
gptkbp:research_focus
|
chronic pain
psychiatric disorders
|
|
gptkbp:research_output
|
ongoing
promising results
further studies needed
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
|
|
gptkbp:sponsor
|
gptkb:Vista_Gen_Therapeutics
government grants
|
|
gptkbp:structure
|
2-amino-6-phosphonohexanoic acid
|
|
gptkbp:target_audience
|
adults
elderly
patients with chronic conditions
|
|
gptkbp:targets
|
gptkb:depression
gptkb:fusion
neuropathic pain
GABA receptor
|
|
gptkbp:bfsParent
|
gptkb:Zy_Versa_Therapeutics
|
|
gptkbp:bfsLayer
|
6
|